HighLife
HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.
€80MFinancing round
LeadSI
Supernova Invest
Activity from announced rounds
Activity in this selectionOct 23, 2026 · Europe · Jan 1, 2026
Supernova Invest is the French deep-technology manager whose own materials identify Quobly and HighLife.
Recorded funding activity
HighLife develops a transcatheter heart-valve system. Exein secures devices, while Moa discovers herbicides. Named seed funds remain separate from the manager-level history.
- Rounds participated in
- 5
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $590M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionExein
Embedded cybersecurity software for device manufacturers that protects connected products from firmware vulnerabilities and malicious activity at runtime.
$270MUndisclosed
ParticipantMoa Technology
An agricultural biotechnology company focused on discovering novel mode of action herbicides
£22.2MSeries C
Role not disclosedQuobly
Develops silicon qubits for dense integration and compatibility with industrial fabrication standards
€115MSeries A
Role not disclosedOrbem
Applies AI to magnetic resonance imaging for non-invasive analysis of biological materials
€55.5MSeries B
Role not disclosed